Hormonal Therapy News and Research RSS Feed - Hormonal Therapy News and Research

Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
Study sheds light on clinical and biological characteristics of male breast cancer

Study sheds light on clinical and biological characteristics of male breast cancer

Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program conducted in both Europe and in the United States and presented at the 2014 San Antonio Breast Cancer Symposium found significant improvement in survival for men with breast cancer, but this improvement was not as good as that observed for women. [More]
Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy. [More]
New studies offer hope for breast cancer survivors struggling with cancer-related pain, swelling

New studies offer hope for breast cancer survivors struggling with cancer-related pain, swelling

Two new studies from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania offer hope for breast cancer survivors struggling with cancer-related pain and swelling, and point to ways to enhance muscular strength and body image. [More]
Generic aromatase inhibitors increase breast cancer treatment adherence by 50%

Generic aromatase inhibitors increase breast cancer treatment adherence by 50%

Although oral hormonal therapy is known to substantially reduce breast cancer recurrence in women with hormone receptor-positive tumors, about one-half of patients fail to take their medications as directed. A new study by Columbia University Medical Center researchers has found that the introduction of generic aromatase inhibitors (the most common type of hormone therapy), which are considerably less expensive than their brand name counterparts, increased treatment adherence by 50 percent. [More]
NAMS set to launch first-ever menopause mobile app

NAMS set to launch first-ever menopause mobile app

The North American Menopause Society is set to launch a first-ever menopause mobile app designed for use by both clinicians and patients to help manage menopausal symptoms and assess risk factors. [More]
Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. [More]
Patient navigation may lead to better breast cancer care in high risk and minority women

Patient navigation may lead to better breast cancer care in high risk and minority women

Patient navigation, or the linking of a newly diagnosed cancer patient with a professional trained in assisting patients though the complex journey of cancer diagnosis and treatment, may lead to better breast cancer care in high risk and minority women. [More]
Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized-but some cases simply do not respond to this treatment. [More]
Dieting may decrease chances for metastases in triple negative breast cancers

Dieting may decrease chances for metastases in triple negative breast cancers

Calorie restriction, a kind of dieting in which food intake is decreased by a certain percentage, has been touted as way to help people live longer. [More]
Prostate cancer breakthroughs offer new hope for men

Prostate cancer breakthroughs offer new hope for men

Men have lower life expectancy than women. This discrepancy is especially pronounced for African American men who live 6 fewer years than women. According to the CDC, life expectancy in the US is 76 years for men compared to 81 for women. [More]
Genetic testing may help select women with ER+ breast cancer for extended hormone therapy

Genetic testing may help select women with ER+ breast cancer for extended hormone therapy

Genetic analyses of results from 1125 postmenopausal women being treated for oestrogen responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from ten years of hormone therapy rather than five. [More]
Molecular subtyping determines breast cancer patients at high risk of disease recurrence

Molecular subtyping determines breast cancer patients at high risk of disease recurrence

A method called molecular subtyping can help doctors better determine which of their breast cancer patients are at high risk of getting breast cancer again, a new study led by the University of South Florida reports. [More]
GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2013. [More]
ASTRO, SSO guideline focuses on reducing ipsilateral breast tumor recurrence in stages I, II breast cancer

ASTRO, SSO guideline focuses on reducing ipsilateral breast tumor recurrence in stages I, II breast cancer

The American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO) are pleased to announce the publication of the consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. [More]
Patients receiving APBI after breast-conserving surgery show excellent tumor control, breast cosmesis

Patients receiving APBI after breast-conserving surgery show excellent tumor control, breast cosmesis

Long-term outcomes of breast cancer patients receiving adjuvant accelerated partial breast irradiation after breast-conserving surgery show excellent tumor control and breast cosmesis (cosmetic outcomes) with minimal late toxicity, according to a study published in the February 1, 2014 print edition of the International Journal of Radiation Oncology. [More]
Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found. The findings indicate that Z-endoxifen, co-developed by Mayo Clinic Cancer Center and the National Cancer Institute, may provide a new and better treatment for some women with estrogen positive breast cancer and, in particular, for those women who do not respond to tamoxifen and aromatase inhibitors. [More]
Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a National Institutes of Health-supported randomized controlled clinical trial. [More]
Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. [More]
Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

An interim study by Italian researchers showed that using a modelling programme together with IPSS and dosage measure can predict the severity of acute urinary symptoms in patients with early prostate cancer who underwent radiotherapy. [More]
Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Cancer can be treated by a number of different ways depending on the location, grade and stage of tumour. A patient's age, medical history and lifestyle will also be taken into consideration and a combination of treatments will also be adopted to provide maximum effect. [More]